These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

122 related articles for article (PubMed ID: 17363137)

  • 1. Use of hecate-chorionic gonadotropin beta conjugate in therapy of lutenizing hormone receptor expressing gonadal somatic cell tumors.
    Rivero-Müller A; Vuorenoja S; Tuominen M; Wacławik A; Brokken LJ; Ziecik AJ; Huhtaniemi I; Rahman NA
    Mol Cell Endocrinol; 2007 Apr; 269(1-2):17-25. PubMed ID: 17363137
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Targeted therapy for adrenocortical tumors in transgenic mice through their LH receptor by Hecate-human chorionic gonadotropin beta conjugate.
    Vuorenoja S; Rivero-Müller A; Ziecik AJ; Huhtaniemi I; Toppari J; Rahman NA
    Endocr Relat Cancer; 2008 Jun; 15(2):635-48. PubMed ID: 18509010
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A novel targeted therapy of Leydig and granulosa cell tumors through the luteinizing hormone receptor using a hecate-chorionic gonadotropin beta conjugate in transgenic mice.
    Bodek G; Vierre S; Rivero-Müller A; Huhtaniemi I; Ziecik AJ; Rahman NA
    Neoplasia; 2005 May; 7(5):497-508. PubMed ID: 15967102
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Targeting breast and prostate cancers through their hormone receptors.
    Leuschner C; Hansel W
    Biol Reprod; 2005 Nov; 73(5):860-5. PubMed ID: 16033998
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Hecate-CGbeta conjugate and gonadotropin suppression shows two distinct mechanisms of action in the treatment of adrenocortical tumors in transgenic mice expressing Simian Virus 40 T antigen under inhibin-alpha promoter.
    Vuorenoja S; Mohanty BP; Arola J; Huhtaniemi I; Toppari J; Rahman NA
    Endocr Relat Cancer; 2009 Jun; 16(2):549-64. PubMed ID: 19261682
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effects of a lytic peptide conjugated to beta HCG on ovarian cancer: studies in vitro and in vivo.
    Gawronska B; Leuschner C; Enright FM; Hansel W
    Gynecol Oncol; 2002 Apr; 85(1):45-52. PubMed ID: 11925119
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A novel approach of targeted ablation of mammary carcinoma cells through luteinizing hormone receptors using Hecate-CGbeta conjugate.
    Bodek G; Rahman NA; Zaleska M; Soliymani R; Lankinen H; Hansel W; Huhtaniemi I; Ziecik AJ
    Breast Cancer Res Treat; 2003 May; 79(1):1-10. PubMed ID: 12779076
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Targeted destruction of normal and cancer cells through lutropin/choriogonadotropin receptors using Hecate-betaCG conjugate.
    Zaleska M; Bodek G; Jana B; Hansel W; Ziecik AJ
    Exp Clin Endocrinol Diabetes; 2003 May; 111(3):146-53. PubMed ID: 12784188
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Targeted ablation of prostate carcinoma cells through LH receptor using Hecate-CGbeta conjugate: functional characteristic and molecular mechanism of cell death pathway.
    Bodek G; Kowalczyk A; Waclawik A; Huhtaniemi I; Ziecik AJ
    Exp Biol Med (Maywood); 2005 Jun; 230(6):421-8. PubMed ID: 15956772
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Destruction of breast cancers and their metastases by lytic peptide conjugates in vitro and in vivo.
    Hansel W; Enright F; Leuschner C
    Mol Cell Endocrinol; 2007 Jan; 260-262():183-9. PubMed ID: 17101210
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Growth repression in diethylstilbestrol/dimethylbenz[a]anthracene-induced rat mammary gland tumor using Hecate-CGbeta conjugate.
    Zaleska M; Waclawik A; Bodek G; Zezula-Szpyra A; Li X; Janowski T; Hansel WH; Rahman NA; Ziecik AJ
    Exp Biol Med (Maywood); 2004 Apr; 229(4):335-44. PubMed ID: 15044717
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Human prostate cancer cells and xenografts are targeted and destroyed through luteinizing hormone releasing hormone receptors.
    Leuschner C; Enright FM; Gawronska-Kozak B; Hansel W
    Prostate; 2003 Sep; 56(4):239-49. PubMed ID: 12858351
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Conjugates of lytic peptides and LHRH or betaCG target and cause necrosis of prostate cancers and metastases.
    Hansel W; Leuschner C; Enright F
    Mol Cell Endocrinol; 2007 Apr; 269(1-2):26-33. PubMed ID: 17382461
    [TBL] [Abstract][Full Text] [Related]  

  • 14. High levels of luteinizing hormone analog stimulate gonadal and adrenal tumorigenesis in mice transgenic for the mouse inhibin-alpha-subunit promoter/Simian virus 40 T-antigen fusion gene.
    Mikola M; Kero J; Nilson JH; Keri RA; Poutanen M; Huhtaniemi I
    Oncogene; 2003 May; 22(21):3269-78. PubMed ID: 12761497
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Targeted destruction of prostate cancer cells and xenografts by lytic peptide-betaLH conjugates.
    Hansel W; Leuschner C; Gawrońska B; Enright F
    Reprod Biol; 2001 Jul; 1(1):20-32. PubMed ID: 14666172
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Expression and regulation of luteinizing hormone/human chorionic gonadotropin receptors in ovarian cancer and its correlation to human chorionic gonadotropin-doxorubicin sensitivity.
    Gebauer G; Mueller N; Fehm T; Berkholz A; Beck EP; Jaeger W; Licht P
    Am J Obstet Gynecol; 2004 Jun; 190(6):1621-8; discussion 1628. PubMed ID: 15284756
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Assessment of luteinizing hormone receptor function in an endometrial cancer cell line, Ishikawa cells in response to human chorionic gonadotrophin (hCG).
    Viswanath G; Chatterjee S; Roy P
    Mol Cell Endocrinol; 2007 Jun; 272(1-2):14-21. PubMed ID: 17548147
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Luteinizing hormone-induced up-regulation of ErbB-2 is insufficient stimulant of growth and invasion in ovarian cancer cells.
    Warrenfeltz SW; Lott SA; Palmer TM; Gray JC; Puett D
    Mol Cancer Res; 2008 Nov; 6(11):1775-85. PubMed ID: 19010824
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Membrane disrupting lytic peptide conjugates destroy hormone dependent and independent breast cancer cells in vitro and in vivo.
    Leuschner C; Enright FM; Gawronska B; Hansel W
    Breast Cancer Res Treat; 2003 Mar; 78(1):17-27. PubMed ID: 12611453
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Gonadal defects and hormonal alterations in transgenic mice expressing a single chain human chorionic gonadotropin-lutropin receptor complex.
    Meehan TP; Harmon BG; Overcast ME; Yu KK; Camper SA; Puett D; Narayan P
    J Mol Endocrinol; 2005 Apr; 34(2):489-503. PubMed ID: 15821112
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.